SRR | Jotup

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the European Patent Office

Retrieved on:

Tuesday, April 2, 2024

Salt, Progression-free survival, Patient, EPO, MD, Pembrolizumab, Human, Therapy, European Patent Convention, Safety, Pharmacokinetics, Randomized controlled trial, Patent, EP, Animal, SRR, Pharmaceutical industry

HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.

Key Points:

European Patent 3,823,617 Issued on March 6, 2024
HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.
"We are extremely pleased that the EPO has issued this composition of matter patent," commented Patrick Mooney, MD, CEO of Linnaeus.
As we continue to collect very promising data from our clinical trials with LNS8001, we will continue to prosecute the claims in this patent worldwide."
The study will enroll 135 patients who will be selected based on a predictive biomarker and then randomized to receive LNS8801 alone, LNS8801 and pembrolizumab, or physician's choice therapy.

Successful Completion of System Requirements & Design Review Demonstrates Progress Toward Q4 Launch of Innovative Precision Positioning, Navigation and Timing Payload

Retrieved on:

Tuesday, February 20, 2024

Data Management, Aerospace, Technology, Manufacturing, Other Communications, Communications, Satellite, Telecommunications, Internet, Engineering, Mobile, Wireless, SRR, Knowledge, SDR, System Design Review

The SRR and SDR are important program milestones marking the baselining of the requirements for the mission and design of the navigation payload into Sidus’ commercially developed, owned, and operated small satellite.

Key Points:

The SRR and SDR are important program milestones marking the baselining of the requirements for the mission and design of the navigation payload into Sidus’ commercially developed, owned, and operated small satellite.
The SRR reviewed team specifications to ensure they reflect the current knowledge of the mission and market requirements to serve as a stable baseline to proceed with development.
The Sidus team is maturing the design of its customer’s payload for an expected integration for launch later this year.
All parties agreed the LS-3 integrated architecture safely meets approved mission success criteria on schedule and within budget.

Red Cat Reports Preliminary Record Revenue 16% Above Guidance for Third Quarter of Fiscal 2024 and Increases Guidance for Fourth Quarter 2024

Retrieved on:

Wednesday, February 14, 2024

SAN, Government, SRR, Replicator, RCAT, Software

“We had record shipments of the Teal 2 in the third quarter, as our backlog hit a new company record.

Key Points:

“We had record shipments of the Teal 2 in the third quarter, as our backlog hit a new company record.
We expect fourth quarter to be an exciting and fruitful quarter after the last 12 months of business development in NATO countries and Saudi Arabia.”
“Teal’s autonomous, attritable, and open technology is seeing huge demand in America and around the world,” said George Matus, CTO of Red Cat.
“We develop vertically integrated products and scale them through volume production in our brand new factory in Salt Lake City.
Red Cat is here to fully support the warfighter and the paradigm shift actively happening toward our technology with programs like SRR, Replicator, and beyond.”

Red Cat Integrates Advanced AI Capabilities into Next-Generation Drone System for the U.S. Army’s Short Range Reconnaissance Program

Retrieved on:

Tuesday, January 23, 2024

Classification, Artificial intelligence, Thermal, SRR, SAN, RCAT, Government, Ecosystem, Software, ISR, Teal, Teledyne FLIR, Teledyne Technologies, Intelligence, Army

Teal was recently selected by the Department of Defense’s Defense Innovation Unit and the U.S. Army as one of two finalists competing in the SRR program.

Key Points:

Teal was recently selected by the Department of Defense’s Defense Innovation Unit and the U.S. Army as one of two finalists competing in the SRR program.
The program’s goal is to provide small, rucksack-portable sUAS capabilities to Army platoons for situational awareness beyond the next terrain feature.
“Teal’s solution is the first to integrate this kind of advanced artificial intelligence and real-time processing onboard the aircraft itself.
It is both Blue UAS Certified, which indicates its approval by the Department of Defense, and FAA Remote ID approved.

Skydio Enters Final Phase of U.S. Army’s Short Range Reconnaissance Tranche 2 Program

Retrieved on:

Wednesday, January 10, 2024

Skydio , the leading U.S. drone manufacturer and world leader in autonomous flight technology, today announced it has entered into the final phase of the U.S. Army’s Short Range Reconnaissance (SRR) tranche 2 program, where it intends to deliver the powerful Skydio X10D small UAS (sUAS), the next generation of autonomous drone technology.

Key Points:

Skydio , the leading U.S. drone manufacturer and world leader in autonomous flight technology, today announced it has entered into the final phase of the U.S. Army’s Short Range Reconnaissance (SRR) tranche 2 program, where it intends to deliver the powerful Skydio X10D small UAS (sUAS), the next generation of autonomous drone technology.
Skydio remains the solution provider of record for the U.S. Army’s Short Range Reconnaissance program, which it won in November 2021 .
The Skydio X10 platform combines new, cutting-edge data capture cameras, unparalleled autonomy, and versatile hardware to serve a range of industries, including defense, public safety, and utilities.
The SRR program is designed to equip soldiers with a rapidly deployable small UAS solution to conduct reconnaissance and surveillance (R&S) activities.

Red Cat Holdings Reports Financial Results for Fiscal Second Quarter 2024 and Provides Corporate Update

Retrieved on:

Friday, December 15, 2023

SRR, RCAT, Government, ISR, Interest, Software, Teal, SAN, PAR, Growth, War, Webcast, ATAK, Intelligence, Video game

SAN JUAN, Puerto Rico, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, reports its financial results for the second quarter ended October 31, 2023 and provides a business update.

Key Points:

SAN JUAN, Puerto Rico, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, reports its financial results for the second quarter ended October 31, 2023 and provides a business update.
This technology stack gives the frontline warfighter a feature-rich capability never seen on a rucksack portable drone.
ET on Friday, December 15, 2023 to review financial results and provide an update on corporate developments.
Callers should dial in approximately ten minutes prior to the start time and ask to be connected to the Red Cat conference call.

Red Cat Holdings Selected by U.S. Army as Finalist for Short Range Reconnaissance Tranche 2 Drone Program

Retrieved on:

Thursday, December 14, 2023

SRR, Government, RCAT, ISR, Software, Army, SAN, DIU, Artificial intelligence, Intelligence, Red

Teal was previously one of three drone manufacturers selected to develop a next-generation small unmanned aerial system (sUAS) designed for intelligence, surveillance, and reconnaissance (ISR) for the U.S. Army.

Key Points:

Teal was previously one of three drone manufacturers selected to develop a next-generation small unmanned aerial system (sUAS) designed for intelligence, surveillance, and reconnaissance (ISR) for the U.S. Army.
The ultimate goal of the SRR program is to provide small, rucksack portable sUAS capabilities to Army platoons (20-50 soldiers) for situational awareness beyond the next terrain feature.
“I’m excited to advance our collaboration with the U.S. Army as we seek to provide the ideal solution for SRR.
The drone is designed to support U.S. military operations, public safety organizations, and U.S. government agencies in a variety of environments.

Red Cat Announces Management Changes

Retrieved on:

Tuesday, November 28, 2023

SRR, Government, SPA, RCAT, Unusual, Sale, Software, Acquisition, Army, Teal, SAN, Consumer, Artificial intelligence, Employment

SAN JUAN, Puerto Rico, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announces several management changes.

Key Points:

SAN JUAN, Puerto Rico, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announces several management changes.
George Matus, founder and CEO of wholly owned subsidiary, Teal Drones, has been appointed as Chief Technology Officer of Red Cat.
"Since Red Cat acquired Teal in August 2021, George has been instrumental in leading the Company's efforts to secure the Army's Short-Range Reconnaissance(SRR) contract.
If the transaction is completed, Red Cat would become the largest shareholder in UM, and the shareholders of Red Cat will continue to benefit from Allan's leadership skills."

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Retrieved on:

Thursday, December 21, 2023

ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg).

Key Points:

ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg).
The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
The primary objective was to demonstrate immunological non-inferiority of ARCT-154 to Comirnaty®, as measured by neutralizing antibodies against Wuhan-Hu-1 SARS-CoV-2.
Key secondary objectives included the assessment of immunological non-inferiority and superiority against the Omicron BA.4/5 subvariant and vaccine tolerability assessed using participant-completed electronic diaries.

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Retrieved on:

Thursday, December 21, 2023

KING OF PRUSSIA, Pa. and SAN DIEGO, Dec. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®. ARCT-154 results were achieved with one-sixth the dose of Comirnaty® (5 μg vs 30 μg).

Key Points:

Both vaccines were well-tolerated, with no causally associated severe or serious adverse events.
The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
"This study represents the first phase of CSL and Arcturus' plans to launch this innovative vaccine platform globally."
Key secondary objectives included the assessment of immunological non-inferiority and superiority against the Omicron BA.4/5 subvariant and vaccine tolerability assessed using participant-completed electronic diaries.